Physician profile
Lisa Malter
NPI 1487852158
$54,569.16
in general payments reported to CMS, 2019-2025
13 companies · $17K in 2025
The $17K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $2,030 · 2021: $13K · 2022: $6,312 · 2023: $12K · 2024: $3,877 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Honoraria: $1,800 · Food and Beverage: $897 · Travel and Lodging: $867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,990.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,100.00 |
| Honoraria | $1,800.00 |
| Food and Beverage | $897.27 |
| Travel and Lodging | $866.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17,472.82 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $13,664.73 | 2022-2024 | |
| Lilly USA, LLC | $6,575.00 | 2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $3,876.04 | 2019-2021 | |
| Abbvie INC. | $3,772.94 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $2,047.50 | 2021 | |
| Gilead Sciences, INC. | $2,030.00 | 2020 | |
| Celltrion USA INC. | $1,896.65 | 2023 | Zymfentra, Yuflyma |
| Pharmacosmos Therapeutics INC. | $1,250.00 | 2024 | Monoferric |
| Janssen Biotech, INC. | $1,233.64 | 2022-2025 | Tremfya |
| Celgene Corporation | $609.98 | 2023 | Zeposia |
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| Apollo Endosurgery US INC | $14.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Malter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.